Pharmaceutical

BNT-325 by Duality Biologics (Shanghai) for Metastatic Ovarian Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer.

Jul 6, 2024 - 04:00
BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer.
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

Next Article

Hexagonal perovskite oxides: Electrolytes for next-generation protonic ceramic f...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: A controversial new study examines traditional Chinese medicine’s potential cardiac benefits

STAT+: A controversial new study examines traditional C...

Oct 24, 2023

Treatment options for Crohn’s disease expand after Rinvoq approval

Treatment options for Crohn’s disease expand after Rinv...

May 20, 2023

STAT+: South Africa investigates Johnson & Johnson over ‘excessive pricing’ for its TB drug

STAT+: South Africa investigates Johnson & Johnson over...

Sep 16, 2023